Biodistribution, pharmacokinetics and toxicity evaluation of mannosylated gelatin nanoparticles of linezolid for anti-tubercular therapy

References

• Esmail H, Barry CE, Young DB, et al. The ongoing challenge of latent tuberculosis. Philos Trans R Soc B Biol Sci. 2014;369(1645):20130437.
   PubMed Web of Science ®Google Scholar
• Dutta NK, Karakousis PC. Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev. 2014;78:343–371.
   PubMed Web of Science ®Google Scholar
• Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
   PubMed Web of Science ®Google Scholar
• Senior K. FDA approves first drug in new class of antibiotics. Lancet. 2000;355(9214):1523.
   PubMed Web of Science ®Google Scholar
• Barrett JF. Linezolid Pharmacia Corp. Curr Opin Investig Drugs. 2000;1(2):181–187. http://www.ncbi.nlm.nih.gov/pubmed/11249571
   PubMedGoogle Scholar
• Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Physician. 2002;65:663–670.
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother. 2005;6(13):2315–2326.
   PubMed Web of Science ®Google Scholar
• Yang C, Lei H, Wang D, et al. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis. 2012;65(3):240–242. http://www.ncbi.nlm.nih.gov/pubmed/22627306
   PubMed Web of Science ®Google Scholar
• Singh B, Cocker D, Ryan H, et al. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;1:1–83.
   Google Scholar
• Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug‐resistant tuberculosis. Clin Infect Dis. 2010;50:49–55.
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42:3251–3255.
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113–119.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Mendes RE, Hogan PA, et al. Linezolid surveillance results for the United States (LEADER surveillance program 2014). Antimicrob Agents Chemother. 2016;60:2273–2280.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Hogan PA, Streit JM, et al. Update on Linezolid in vitro activity through the zyvox annual appraisal of potency and spectrum program. Antimicrob Agents Chemother. 2015;59:2454–2457.
   PubMed Web of Science ®Google Scholar
• Bouza E, Muñoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect. 2001;7:75–82.
   PubMed Web of Science ®Google Scholar
• Pfizer C. “Zyvox” linezolid - injection and tablets for oral suspension. Pfizer Drug Man. 2010;1–35.
   Google Scholar
• Kishor K, Dhasmana N, Kamble SS, et al. Linezolid induced adverse drug reactions - an update. Curr Drug Metab. 2015;16:553–559. http://www.ncbi.nlm.nih.gov/pubmed/26424176
   PubMed Web of Science ®Google Scholar
• Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:20.
   PubMedGoogle Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42:742–755.
   PubMedGoogle Scholar
• Paradise J. Regulating nanomedicine at the food and drug administration. AMA J Ethics. 2019;21:E347E355.
   Google Scholar
• Soares S, Sousa J, Pais A, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360.
   PubMed Web of Science ®Google Scholar
• Kudgus RA, Walden CA, McGovern RM, et al. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep. 2015;4:5669.
   Web of Science ®Google Scholar
• Raza K, Kumar P, Kumar N, et al. Pharmacokinetics and biodistribution of the nanoparticles, in: adv. Nanomedicine Deliv. Ther Nucleic Acids. Elsevier. 2017:165–186. DOI:https://doi.org/10.1016/B978-0-08-100557-6.00009-2.
   Google Scholar
• Coester KJ, Langer K, Van BH. Gelatin nanoparticles by two-step desolvation-a new preparation method, surface modifications and cell uptake. J. Microencapsul. 2000;17:187–193.
   Google Scholar
• Mitchell JP, Roberts KD, Langley J, et al. A direct method for the formation of peptide and carbohydrate dendrimers. Bioorg Med Chem Lett. 1999;9:2785–2788.
   PubMed Web of Science ®Google Scholar
• Kale RN, Bajaj AN. Ultraviolet spectrophotometric method for determination of gelatin crosslinking in the presence of amino groups. J Young Pharm. 2010;2:90–94.
   PubMedGoogle Scholar
• Sashidhar RB, Capoor AK, Ramana D. Quantitation of ϵ-amino group using amino acids as reference standards by trinitrobenzene sulfonic acid: A simple spectrophotometric method for the estimation of hapten to carrier protein ratio. J Immunol Methods. 1994;167:121–127.
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target. 2011;19:219–227.
   PubMed Web of Science ®Google Scholar
• Patil K, Bagade S, Bonde S. QbD-enabled stability-indicating assay method for the estimation of linezolid in newly developed gelatin nanoparticles for anti-tubercular therapy. Chromatographia. 2020;1–12. DOI:https://doi.org/10.1007/s10337-020-03925-9
   Google Scholar
• Saraogi GK, Gupta P, Gupta UD, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm. 2010;385:143–149.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Clogston JD, Neun BW, et al. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 2008;8:2180–2187.
   PubMed Web of Science ®Google Scholar
• Math MV, Kattimani YR, Khadkikar RM, et al. Red blood cell count: brief history and new method. MGM J Med Sci. 2016;3:116–119.
   Google Scholar
• OECD/OECDE. Test No. 407: repeated dose 28-day oral toxicity study in rodents. OECD Guidel Test Chem. 2008. 1–13. DOI:https://doi.org/10.1787/9789264070684-en.
   Google Scholar
• Costa A, Sarmento B, Seabra V. Targeted drug delivery systems for lung macrophages. Curr Drug Targets. 2015;16:1565–1581.
   PubMed Web of Science ®Google Scholar
• Tomihata K, Ikada Y. Cross-linking of gelatin with carbodiimides. Tissue Eng. 1996;2:307–313.
   PubMedGoogle Scholar
• Patil K, Bagade S, Bonde S, et al. Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities. Biomed Pharmacother. 2018;99:735–745.
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen Z, Li Y, et al. Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis : preparation and in vitro characterization. Drug Des Devel Ther. 2017;11:585–592.
   PubMed Web of Science ®Google Scholar